ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintTitle ChevronIcon Twitter
Health Technology

Suzuken Co., Ltd.

Business Summary

Suzuken Co., Ltd. engages in the pharmaceutical business. It operates through the following segments: Pharmaceutical Wholesale, Pharmaceutical Manufacturing, Insurance Pharmacy, and Healthcare-related Services. The Pharmaceutical Wholesale segment sells pharmaceuticals, diagnostic reagents, medical equipment, and supplies. The Pharmaceutical Manufacturing segment manufactures and sells pharmaceuticals and diagnostic reagents. The Insurance Pharmacy segment prepares medicines based on prescriptions from medical institutions. The Healthcare-related Services segment includes medical book sales, medical device manufacturing, and drug transportation businesses. The company was founded by Kenzo Suzuki on November 13, 1932 and is headquartered in Nagoya, Japan.

Financial Highlights

Mar 2020 JPYUSD
Revenue2,213.53B20,358.85M
Gross Profit194,124M1,785.44M
Operating income32,572M299.57M
Income before tax41,808M384.52M
Net income28,213M259.48M
EBITDA43,998M404.66M
Diluted EPS310.262.85
Dividends Per Share720.66
Total Assets1,112.50B10,305.28M
Total liabilities699,796M6,482.29M
Total equity411,839M3,814.91M
Operating cash flow-25,817M-237.45M
Currency in JPYCurrency in USD

Historical Data

 Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020
Revenue 2,228.20B 2,127.07B 2,124.01B 2,132.34B 2,213.53B
Gross Profit 202,463M 193,225M 187,512M 189,295M 194,124M
Operating income 28,244M 18,712M 19,737M 27,229M 32,572M
Income before tax 45,020M 32,301M 28,766M 45,479M 41,808M
Net income 28,960M 21,309M 18,821M 30,205M 28,213M
EBITDA 41,178M 31,407M 31,800M 38,788M 43,998M
Diluted EPS 292.12 216.92 198.21 322.72 310.26
Dividends Per Share 69 54 64 69 72
Total Assets 1,178.43B 1,109.01B 1,173.32B 1,189.23B 1,112.50B
Total liabilities 784,337M 712,513M 766,896M 787,611M 699,796M
Total equity 393,623M 395,944M 405,752M 400,775M 411,839M
Operating cash flow 20,457M 27,013M 98,066M 41,751M -25,817M
 Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020
Revenue 18,555.33M 19,642.85M 19,164.21M 19,228.56M 20,358.85M
Gross Profit 1,686.00M 1,784.37M 1,691.85M 1,706.98M 1,785.44M
Operating income 235.20M 172.79M 178.07M 245.53M 299.57M
Income before tax 374.90M 298.28M 259.54M 410.10M 384.52M
Net income 241.16M 196.78M 169.81M 272.37M 259.48M
EBITDA 342.90M 290.03M 286.91M 349.77M 404.66M
Diluted EPS 2.43 2.00 1.78 2.91 2.85
Dividends Per Share 0.57 0.49 0.57 0.62 0.66
Total Assets 10,484.76M 9,952.54M 11,032.68M 10,744.34M 10,305.28M
Total liabilities 6,978.39M 6,394.26M 7,211.05M 7,115.78M 6,482.29M
Total equity 3,502.13M 3,553.29M 3,815.25M 3,620.86M 3,814.91M
Operating cash flow 170.35M 249.45M 884.81M 376.49M -237.45M

Valuation Measures

Mar 2020
PER12.68
ROA2.45%
ROE6.94%
Operating margin1.47%
Profit margin1.27%

Key executives

  • Executive President & Representative Director: Hiromi Miyata
  • Executive Officer & Manager-Information Systems: Toyoake Ota
  • Executive Officer & Manager-Compliance: Asako Tomita
  • Director & Executive Vice President: Shigeru Asano
  • Executive Officer & Manager-Osaka Sales: Osamu Abe

Shareholders

  • Suzuken Co., Ltd. (13.6%)
  • Shionogi & Co., Ltd. (3.1%)
  • BESSHO HIROKO (2.9%)
  • Nomura Asset Management Co., Ltd. (2.3%)
  • IZAWA HISAYO (2.3%)
  • BlackRock Fund Advisors (2.1%)
  • Suzuken Group Employee Stock Ownership Plan (2.1%)
  • The Vanguard Group, Inc. (2.0%)
  • Silchester International Investors LLP (1.8%)
  • BESSHO YOSHIKI (1.8%)

Contact Details

  • Website:http://www.suzuken.co.jp
  • Address: 8 Higashi Kataha-machi, Higashi-Ku, Nagoya, 461-8701, Japan
  • Phone: +81.52.961.2331

Related Companies

  • S.D. Collabo Co., Ltd.
  • S-Care Mate Co., Ltd.
  • Life Medicom Co., Ltd.
  • Suzuken Restricted Stock Compensation Plan
  • Suzuken Trust
  • Suzuken Medical Information Bank KK
  • Ryomo Iyakuhin KK
  • Nakano Yakuhin KK
  • Medicis KK
  • Suzuken Okinawa Yakuhin KK
  • Chugoku Farmacy KK
  • Astis Co., Ltd.
  • Akiyama Butsuryu Service KK
  • Sanki Wellbe KK
  • Owl Chozai KK
  • Suzuken Logicom Corp.
  • Pfercos Co., Ltd.
  • Suzuken Iwate Co., Ltd.
  • Kenzmedico Co., Ltd.
  • Sanki Corp.
  • Akiyama, Inc.
  • Pfercos KK
  • Jingu Yakuhin KK
  • Omori Yakuhin Co. Ltd.
  • Shoyaku Co., Ltd.
  • Okinawa Yakuhin
  • Sanki Co., Ltd. /Medical/
  • Suzuken Group Employee Stock Ownership Plan
  • Chuo Unyu Co., Ltd.
  • Astis (Eiwa) Co., Ltd.

Competitors

  • Cara Therapeutics Inc
  • Sienna Biopharmaceuticals, Inc.
Last Updated on 4 Dec, 2020

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends October 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more